Please enter your license information:
Safety Information
Safety information.
Trajenta®1
Clinical use
No dosage adjustment is required based on age, however, greater sensitivity in some older individuals cannot be ruled out.
Safety and effectiveness has not been established in pediatric patients (<18 years of age), therefore Trajenta® should not be used in this patient population.
Contraindications
Relevant warnings and precautions
- An association between DPP-4i treatment and heart failure was observed in cardiovascular outcomes trials for two other members of the DPP-4i class
- Hypoglycemia: caution when used in combination with a sulfonylurea or insulin
- Loss of glycemic control may occur in periods of stress
- Use with strong inducers of P-gp or CYP3A4 (blood glucose monitoring recommended)
- Not recommended in patients with severe hepatic impairment
- Monitor for signs and symptoms of pancreatitis
- Clinical trial/post-marketing reports of serious hypersensitivity reactions
- Immunocompromised patients (consider monitoring lymphocyte count)
- Monitor blood glucose and HbA1c levels periodically
- Assess hepatic function before starting treatment and periodically thereafter
- Use with caution in patients with end-stage renal disease (ESRD) and those on dialysis
- No studies on the effect on human fertility have been conducted
- Ulcerative and necrotic skin lesions (monitoring for skin disorders is recommended)
- Cases of bullous pemphigoid
- Not recommended in pregnant and nursing women
For more information
Please refer to the Product Monograph at www.TrajentaPM.ca for important information relating to adverse events, drug interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.
Jentadueto®15
Jentadueto® (linagliptin/metformin hydrochloride tablets) is indicated as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus who are inadequately controlled on metformin, or already controlled with the free combination of linagliptin and metformin.
Jentadueto® (linagliptin/metformin hydrochloride tablets) is indicated as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with a sulfonylurea, when dual therapy with metformin and a sulfonylurea do not provide adequate glycemic control, or in combination with basal insulin, when dual therapy with metformin and basal insulin do not provide adequate glycemic control.
Please refer to the Product Monograph at www.JentaduetoPM.ca for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.
Are you thinking Trajenta®?
![Healthcare professional and patient Healthcare professional and patient](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/login-banner-updated.png)
Are you a Canadian
View coverage details for Trajenta® and Jentadueto®
![Map of Canada Map of Canada](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/check-coverage-icon.png)